> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# AbbVie sNDA for Qulipta to Prevent Chronic Migraine
- URL: https://www.fdaweb.com/abbvie-snda-for-qulipta-to-prevent-chronic-migraine/
- Published: 2022-06-24T12:00:00.000Z
- Updated: 2026-09-14T17:49:58.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5152155

AbbVie has submitted an sNDA to FDA for a new indication for its Qulipta (atogepant) as a preventive treatment for chronic migraine. The company [says](https://news.abbvie.com/article%5Fprint.cfm?article%5Fid=12462&ref=fdaweb.com) the submission was based on the Phase 3 PROGRESS chronic migraine study evaluating Qulipta in adults who met the primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo.

Qulipta was approved by FDA in 9/2021 for the preventive treatment of adults with episodic migraine. It is described as the first and only gepant (oral calcitonin gene-related peptide receptor antagonist) developed specifically for the preventive treatment of migraine.